Seelos Therapeutics(SEEL) - 2021 Q2 - Quarterly Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 For the transition period from to Commission File Number 000-22245 SEELOS THERAPEUTICS, INC. FORM 10-Q (Exact Name of Registrant as Specified in Its Charter) (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 Nevada 87-0449967 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification No.) OR ☐ TRANSITION RE ...